A new study compares the safety and effectiveness of high- and low-frequency spinal cord stimulation (SCS) therapy for relieving chronic back and leg pain.
The study, published recently in Anesthesiology, the official journal of the American Society of Anesthesiologists, suggests that a new high-frequency form of SCS therapy may help deliver greater, long-term relief of chronic back and leg pain than a traditional form of SCS therapy, according to a news release from the American Society of Anesthesiologists.
“Chronic back and leg pain have long been considered difficult to treat, and current pain relief options such as opioids have limited effectiveness and commonly known side effects. Given the prevalence of chronic pain, high-frequency SCS is an exciting advance for our patients,” says the study’s lead author Leonardo Kapural, MD, professor of anesthesiology at Wake Forest University School of Medicine and clinical director at Carolinas Pain Institute at Brookstown in Winston-Salem, NC.
SCS is an increasingly common therapy that delivers electric pulses to the spinal cord, through a small device implanted under the skin, for difficult-to-treat chronic pain in the trunk and limbs. SCS is reversible and is an important option for chronic pain sufferers who otherwise would rely on opioids or back surgery for relief, the release notes.
The new treatment, called HF10™ therapy, uses proprietary high-frequency pulses of 10,000 Hz, compared to traditional SCS which uses frequencies of 40 to 60 Hz. HF10 therapy also provides pain relief without paresthesia—a stimulation-induced sensation commonly perceived as tingling or buzzing, which masks a patient’s perception of pain—typical of traditional SCS.
These sensations are often distracting or uncomfortable to patients and limit the utility and acceptance of traditional devices. Identifying a new intervention that does not rely on paresthesia to mask pain is novel to SCS and has the potential to improve pain relief and quality of life for these patients, the release explains.
In the study, researchers examined 171 patients with chronic back or leg pain who were implanted at 10 comprehensive pain treatment centers. Of these, 90 patients received HF10 therapy, while 81 patients had traditional SCS, per the release.
At 3 months, 85% of back pain and 83% of leg pain patients in the HF10 therapy group experienced a 50% reduction in pain or greater. Conversely, only 44% of back pain and 56% of leg pain patients in the traditional SCS group experienced a 50% reduction in pain.
None of the patients in the HF10 therapy group experienced paresthesia. HF10 therapy remained more effective than traditional SCS over the 12-month study period. More patients in the HF10 therapy group reported being “very satisfied” with their pain relief (55% versus 32%), the release explains.
More than 1.5 billion people worldwide suffer from chronic pain, with lower back pain being the most frequent condition affecting 23% to 26% of the population, the release notes.
[Source(s): American Society of Anesthesiologists, EurekAlert]
